JamieDWeismanMD

Dermatology • Sandy Springs, GA

Dermatologist at Medical Dermatology Specialists, Inc.

Join to view full profile

Dr. Weisman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Weisman's full profile

Already have an account?

Office
5730 Glenridge Drive
Suite T-100
Sandy Springs, GA 30328
Phone+1 404-939-9220

Fax+1 404-939-9221
Is this information wrong?

Education & Training

Emory University School of MedicineResidency, Dermatology, 1999 - 2002
Emory University School of MedicineClass of 1998

Certifications & Licensure

GA State Medical License 2001 - 2025
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification PrimeSUITE EHR, Greenway Health, LLC, 2011-2013

Clinical Trials

Vascular Inflammation in Psoriasis Trial (The VIP Trial) Start of enrollment: 2012 Jul 01
Completed
Phase 4
Vascular Inflammation in Psoriasis - Extension Study Start of enrollment: 2013 Apr 01
Completed
Phase 4
VPD-737 for Treatment of Chronic Pruritus Start of enrollment: 2013 Oct 15
Completed
Phase 2
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) Start of enrollment: 2014 Jun 16
Completed
Phase 3
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Aug 01
Completed
Phase 3
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis Start of enrollment: 2016 Apr 01
Completed
Phase 3
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis Start of enrollment: 2017 Mar 28
Completed
Phase 3
A Study of LY3471851 in Participants With Eczema Start of enrollment: 2019 Dec 04
Completed
Phase 1
A Study of LY3471851 in Participants With Psoriasis Start of enrollment: 2019 Nov 26
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

2 citations
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
Amy S Paller, Carsten Flohr, Lawrence F Eichenfield, Alan D Irvine, Jamie Weisman, Jennifer Soung, Ana Pinto Correia, Chitra R Natalie, Claudia Rodriguez Capriles, Eva...> ;Dermatology and Therapy. 2023 Jul 1
3 citations
Real-World Findings on the Characteristics and Treatment Exposures of Patients with Hidradenitis Suppurativa from US Claims Data.
Amit Garg, Haley B Naik, Afsaneh Alavi, Paul Hazen, Jennifer L Hsiao, Vivian Y Shi, Jamie Weisman, Tanja Tran, Jan Rudnik, Adam Jedrzejczyk, Ingrid Pansar, Alexa B Kim...> ;Dermatology and Therapy. 2023 Feb 1
12 citations
IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study.
Alexa B Kimball, Christian Loesche, Errol P Prens, Falk G Bechara, Jamie Weisman, Izabela Rozenberg, Philip Jarvis, Thomas Peters, Lukas Roth, Grazyna Wieczorek, Frank...> ;Experimental Dermatology. 2022 Oct 1
22 citations
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Tria...
Andrew Blauvelt, Emma Guttman-Yassky, Amy S Paller, Eric L Simpson, Michael J Cork, Jamie Weisman, John Browning, Weily Soong, Xian Sun, Zhen Chen, Matthew P Kosloski,...> ;American Journal of Clinical Dermatology. 2022 May 1
5 citations
Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16.
Jonathan I. Silverberg, Mark Boguniewicz, Jill S. Waibel, Jamie Weisman, Lindsay C. Strowd, Luna Sun, Yuxin Ding, Meghan Feely, Fabio P. Nunes, Eric L. Simpson> ;Dermatology and Therapy. 2021 Nov 30
1 citations
Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patie...
Caitriona Ryan, Lyn Guenther, Peter Foley, J. Weisman, Russel Burge, Gaia Gallo, Kyoungah See, M. McKean-Matthews, C.C. Bertram, Joseph F. Merola> ;Journal of the European Academy of Dermatology and Venereology. 2021 Nov 23
53 citations
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Sophie Glatt, Gregor B.E. Jemec, Seth B Forman, Christopher Sayed, George Schmieder, Jamie Weisman, R. Rolleri, Seth D Seegobin, Dominique Baeten, Lucian Ionescu, Chri...> ;JAMA Dermatology. 2021 Nov 1
212 citations
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
Eric L. Simpson, Amy S. Paller, Elaine C. Siegfried, Mark Boguniewicz, Lawrence Sher, Melinda Gooderham, Lisa A. Beck, Emma Guttman-Yassky, David M. Pariser, Andrew Bl...> ;JAMA Dermatology. 2020 Jan 1
102 citations
Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
Christos C. Zouboulis, Martin M. Okun, Errol P. Prens, Robert Gniadecki, Peter Foley, Charles Lynde, Jamie Weisman, Yihua Gu, David A. Williams, Gregor B.E. Jemec> ;Journal of the American Academy of Dermatology. 2019 Jan 1
5 citations
Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-...
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, Luis Puig, Jamie Weisman, Yves Dutronc, Lisa Farmer Kerr, Dapo Ilo, Lotus Mallbris, Matthias Augustin> ;American Journal of Clinical Dermatology. 2018 Jun 1
9 citations
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque P...
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, Luis Puig, Jamie Weisman, Yves Dutronc, Lisa Farmer Kerr, Dapo Ilo, Lotus Mallbris, Matthias Augustin> ;American Journal of Clinical Dermatology. 2017 Apr 1
21 citations
Comparative Effectiveness of Less Commonly Used Systemic Monotherapies and Common Combination Therapies for Moderate-to-Severe Psoriasis in the Clinical Setting
Junko Takeshita, Shuwei Wang, Daniel B. Shin, Kristina Callis Duffin, Gerald G. Krueger, Robert E. Kalb, Jamie Weisman, Brian R. Sperber, Michael B. Stierstorfer, Bruc...> ;Journal of the American Academy of Dermatology. 2014 Dec 1
Join now to see all

Press Mentions

Dr. Matthew Reschly of Medical Dermatology Specialists, Inc. Is Now Seeing Patients at the New Lawrenceville, GA, ClinicJuly 26th, 2022
Atlanta’s Top Docs Share Their Stories of Unexpected, Inspiring, and Memorable CasesJuly 22nd, 2022
Atlanta Medical Dermatology Specialists Welcomes Dr. Aimen Ismail to the TeamJanuary 29th, 2019